Comparative Pharmacology
Head-to-head clinical analysis: GRANIX versus NEUPOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRANIX versus NEUPOGEN.
GRANIX vs NEUPOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granix (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
Filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. It acts by binding to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and maturation of neutrophils.
5 μg/kg subcutaneously once daily for up to 7 days, or 5 μg/kg subcutaneously once daily for up to 14 days for stem cell mobilization.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days, or until absolute neutrophil count reaches 10,000/mm³ after nadir. For mobilization of peripheral blood progenitor cells: 10 mcg/kg subcutaneously once daily for 6-7 days.
None Documented
None Documented
Terminal half-life approximately 3.5 hours (range 1.8–5.4 h) in healthy subjects; clearance increases with neutrophil recovery due to G-CSF receptor-mediated uptake.
3.5 hours (range 2.5–4.5 hours) in healthy subjects; terminal elimination half-life is prolonged in patients receiving chemotherapy due to decreased clearance, approximately 5.5 hours.
Primarily renal excretion; neutrophil-mediated clearance. <1% unchanged in urine.
Primarily renal; greater than 90% of filgrastim is eliminated via renal excretion as intact protein and degraded metabolites. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor